BR112021021839A2 - Composições imunomodulatórias e métodos - Google Patents

Composições imunomodulatórias e métodos

Info

Publication number
BR112021021839A2
BR112021021839A2 BR112021021839A BR112021021839A BR112021021839A2 BR 112021021839 A2 BR112021021839 A2 BR 112021021839A2 BR 112021021839 A BR112021021839 A BR 112021021839A BR 112021021839 A BR112021021839 A BR 112021021839A BR 112021021839 A2 BR112021021839 A2 BR 112021021839A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
constructs
immunomodulatory compositions
immunomodulatory
Prior art date
Application number
BR112021021839A
Other languages
English (en)
Inventor
Jacob Mandell
Peter Mondics
Surbhi Joshi
Original Assignee
Innate Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Biologics Llc filed Critical Innate Biologics Llc
Publication of BR112021021839A2 publication Critical patent/BR112021021839A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições imunomodulatórias e métodos. são fornecidos aqui métodos e composições que compreendem construções que incluem dois ou mais polipeptídeos efetores bacterianos t3ss truncados. também são fornecidas composições farmacêuticas que compreendem as construções e métodos de tratamento de distúrbios inflamatórios com base na administração de tais construções.
BR112021021839A 2019-05-01 2020-05-01 Composições imunomodulatórias e métodos BR112021021839A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841312P 2019-05-01 2019-05-01
PCT/US2020/030958 WO2020223601A1 (en) 2019-05-01 2020-05-01 Immunomodulatory compositions and methods

Publications (1)

Publication Number Publication Date
BR112021021839A2 true BR112021021839A2 (pt) 2022-01-04

Family

ID=73029361

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021839A BR112021021839A2 (pt) 2019-05-01 2020-05-01 Composições imunomodulatórias e métodos

Country Status (9)

Country Link
US (1) US20220111017A1 (pt)
EP (1) EP3962512A4 (pt)
JP (1) JP2022531389A (pt)
KR (1) KR20220007619A (pt)
CN (1) CN114401730A (pt)
AU (1) AU2020265755A1 (pt)
BR (1) BR112021021839A2 (pt)
CA (1) CA3138860A1 (pt)
WO (1) WO2020223601A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114057861B (zh) * 2021-11-22 2023-11-21 深圳湾实验室坪山生物医药研发转化中心 一种靶向UBE2C的bio-PROTAC人工蛋白
WO2024003387A1 (en) 2022-06-30 2024-01-04 Københavns Universitet Contractile injection system and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5100122B2 (ja) * 2003-10-31 2012-12-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 細菌の病原因子とそれらの使用
WO2006137836A2 (en) * 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
US7291476B1 (en) * 2006-05-11 2007-11-06 Board Of Regents, The University Of Texas System O-acetyltranferases
AU2009226972B2 (en) * 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
AU2014322988B2 (en) * 2013-09-20 2018-12-06 Westfaelische Wilhelms-Universitaet Muenster Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
CN115960919A (zh) * 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
US11103538B2 (en) * 2014-08-12 2021-08-31 University Of Massachusetts Targeting epigenetic regulators using a bacterial delivery system
CA3025423A1 (en) * 2016-05-27 2017-11-30 Synthex, Inc. Protein interfaces
WO2019147988A1 (en) * 2018-01-25 2019-08-01 Innate Biologics Llc Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents

Also Published As

Publication number Publication date
CA3138860A1 (en) 2020-11-05
KR20220007619A (ko) 2022-01-18
CN114401730A (zh) 2022-04-26
JP2022531389A (ja) 2022-07-06
AU2020265755A1 (en) 2021-12-16
US20220111017A1 (en) 2022-04-14
WO2020223601A1 (en) 2020-11-05
EP3962512A4 (en) 2023-01-18
EP3962512A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2020008772A (es) Conjugados de il-15, y sus usos.
WO2018229236A3 (en) COMPOSITIONS COMPRISING BACTERIAL STRAINS
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
WO2017218844A3 (en) Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MD3768284T2 (ro) Compoziţii de entrecoccus flagellin pentru utilizare în terapie
BR112019002371A2 (pt) composições farmacêuticas
CO2020012060A2 (es) Inhibidores de la arginasa
PH12021550611A1 (en) Interleukin 10 Conjugates and Uses Thereof
BR112021021839A2 (pt) Composições imunomodulatórias e métodos
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
PH12020551716A1 (en) Anti-ror antibody constructs
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
CY1124286T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
BR112023020219A2 (pt) Anticorpos anti-il-2r agonistas e métodos de uso
WO2021004958A3 (en) Compositions comprising bacterial strains
BR112022000855A2 (pt) Moduladores de nlrp3
BR112019004992A2 (pt) inibição da sinalização de bmp, compostos, composições e usos destes